Gökhan ÖZYİĞİT, Fadıl AKYOL

Cost-Effectiveness Analysis of Leuprorelin Acetate Atrigelin the Treatment of Prostate Cancer

This study aimed to evaluate the clinical effectiveness and cost of leuprorelin acetate Atrigel (Eligard®) in prostate cancer treatment and calculate its cost-effectiveness compared with other luteinizing hormonereleasing hormone (LHRH) agonists (leuprolide acetate microsphere [Lucrin®], goserelin [Zoladex LA®], and triptorelin [Decapeptyl®]).METHODSThe primary health-related outcome was life-years gained, and effectiveness was measured through the difference between treatment options. Analyses were performed separately for testosterone suppression targets of

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
2. Türkiye Halk Sağlığı Kurumu. Türkiye kanser istatistikleri, 2017. Available at: https://hsgm.saglik.gov.tr/ depo/birimler/kanser-db/istatistik/2014-RAPOR._ uzuuun.pdf. Accessed June 21, 2019.
3. Bethesda MD. SEER cancer stat facts: Prostate cancer. National Cancer Institute, 2019. Available at: https:// seer.cancer.gov/statfacts/html/prost.html. Accessed June 21, 2019.
4. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103(2):117–28.
5. Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol 2015;11(9):1465–74
6. Mottet N, van den Bergh RCN, Briers E, et al. EAU – ESTRO – ESUR - SIOG - Guidelines on Prostate Cancer, 2018. Available from: https://uroweb.org/ wp-content/uploads/EAU-ESUR-ESTRO-SIOG Guidelines-on-Prostate-Cancer-large-text-V2.pdf. Accessed June 21, 2019.
7. Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, et al. Nadir Testosterone after Long Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. J Urol 2015;194(5):1264–70.
8. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010;105(5):648–51.
9. Klotz L, O’Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151–6.
10.Bertaglia V, Tucci M, Fiori C, Aroasio E, Poggio M, Buttigliero C, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11(3):325–30.
11.Raina R, Pahalajani G, Agarwal A, Zippe C. Long term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian J Androl 2007;9(2):253–8.
12.Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard? European Urology Supplements 2005;4(8):30–6.
13.Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–57.
14.D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969–74.
15.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual Seventh Edition; 2010. Available at: https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC%20 7th%20Ed%20Cancer%20Staging%20Manual.pdf. Accessed June 21, 2019.
16.National Comprehensive Cancer Network [homepage on the Internet]. Prostate Cancer (version 2.2019). Available at: http://www.nccn.org/patients. Accessed June 21, 2019.
17.Odeyemi IAO, Berges R, Bolodeoku J. Economic impact of different preparations of leuprolide acetate in the management of advanced prostate cancer. J Med Econ 2007;10(2):135–46.
18.Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. Clinicoecon Outcomes Res 2013;5:257–69.
19.Pisu M, Henrikson NB, Banegas MP, Yabroff KR. Costs of cancer along the care continuum: What we can expect based on recent literature. Cancer 2018;124(21):4181–91.
20.Ouzaid I, Rouprêt M. The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the ‘ELIRE’ observational study. Prog Urol 2011;21(12):866–74. [Article in French]
21.Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res 2011;3:201–9.